Tag: Biocon Ltd

Biocon gains over 2% on bonus issue plan

Biocon gains over 2% on bonus issue plan

08/06/2017 11:47

Shares of Biocon climbed over 2 per cent on the Bombay stock Exchange after the biotechnology major said that its shareholders have approved issue of bonus shares.

Buoyed by the development, shares of the company gained as much as 2.04 per cent to hit an intra-day high of Rs 1018.90 apiece on the Bombay Stock Exchange. The scrip was currently trading at Rs 1014.95 against previous close price of Rs 998.50.

In a similar fashion, stocks of company were trading 1.82 per cent higher at Rs 1,015.95 apiece on the National Stock Exchange.

Meanwhile, the broader benchmark BSE Sensex was trading at 31,243.18, down 28.10 points or 0.09 per cent, at 11:50 hours.

Advertisements
Biocon Q2 consolidated net at Rs 146.7 cr

Biocon Q2 consolidated net at Rs 146.7 cr

21/10/2016 11:54

Biotechnology major Biocon Ltd has posted a consolidated net profit of Rs 146.7 crore in the second quarter ended September 30, 2016, compared to a consolidated net loss of Rs 10.6 crore in the same period a year ago, led by higher income.

Consolidated total income from operations climbed 19.8 per cent at Rs 954 crore in Q2 FY 2016-17 from Rs 796 crore in the year ago period, Biocon Ltd said in a filing to the Bombay Stock Exchange (BSE).

Consolidated total expenses rose 13.7 per cent at Rs 782.4 crore in Q2 FY 2016-17 from Rs 688 crore in the same period a year ago.

The company’s small molecules, biologics and branded formulations business expanded by a robust 15 per cent, 26 per cent and 15 per cent, respectively in Q2 FY 2016-17.

“Our performance in Q2 FY17, was led by strong growth across Small Molecules, Biologics and Research Services. Expansion of our biologics footprint in emerging markets and licensing agreements boosted the revenue further. Our ready-to-use Insulin Glargine pen launched in Japan has been well received which augurs well for this business. The acceptance of our proposed biosimilar Trastuzumab filing for review by EMA was a critical milestone this quarter”, the company said.

Shares of Biocon surged 2.52 per cent at Rs 1,005 a piece at 11:55 AM IST on Friday at the BSE.

Biocon zooms 10% on robust Q1

Biocon zooms 10% on robust Q1

22/07/2016 11:33

Shares of Biocon rallied 10 per cent, hitting 52-week high, on the Bombay Stock Exchange after the company reported a growth of 35 per cent year-on-year in its consolidated net profit of Rs 167 crore for the first quarter ended June 30, 2016.

In a separate release, the company announced regulatory submission for proposed Biosimilar Pegfilgrastim accepted for review by European Medicines agency.

Following the Q1 earnings, shares of drug major gained as much as 9.90 per cent and touched 52-week high in intra-day to trade at Rs 771.00 apiece on Bombay Stock Exchange.

In a similar fashion, stocks of the company rose 9.39 per cent to Rs 766.40 apiece on National Stock Exchange.

Meanwhile, the broader benchmark BSE Sensex was trading at 27,728.75, up 18.35 points, or 0.07 per cent, at 11:35 hours.

Biocon launches Insulin Glargine in Japan

Biocon launches Insulin Glargine in Japan

15/07/2016 11:05

Leading biopharmaceutical company, Biocon Ltd has said that its partner FUJIFILM Pharma Co., Ltd. (FFP) has launched Insulin Glargine in Japan. Insulin Glargine BS Injection Kit (FFP) has been developed & manufactured by Biocon, and is being commercialized by FFP in Japan. The product is a ready-to-use, prefilled disposable pen with 3 ml of 100IU Insulin Glargine. It will provide a high quality, yet affordable, world-class long-acting biosimilar basal Insulin Glargine for patients of diabetes in Japan. There were 7.2 million people with diabetes in Japan in 2015, according to the International Diabetes Federation. The company through its partner aims to capture a significant share of the Japanese Glargine market of USD 144 million, which is the second largest market outside of North America & Europe and is largely dominated by disposable pens. Commenting on the development, Biocon Chairperson & Managing Director, Kiran Mazumdar-Shaw said, “The launch of our biosimilar Insulin Glargine in Japan by our partner, furthers our mission to provide affordable access to high quality biopharmaceuticals for chronic diseases. We believe with FUJIFILM Pharma’s commercial network, we will enable access to this world-class, prefilled disposable pen for better diabetes management for patients in Japan.”

Meanwhile, shares of the company were trading at Rs 719 apiece, up 0.88 per cent from the previous close at 11:42 hours on BSE.